Illumina, Inc. provides sequencing- and array-based solutions for genetic analysis worldwide. The company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The company’s portfolio of integrated systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Principal Products and Technologies The company’s technology platforms support the scale of experimentation necessary for population-scale studies, genome-wide discovery, target selection, and validation studies. Customers use the company’s products to analyze the genome at all levels of complexity, from whole-genome sequencing to targeted panels. Most of the company’s product sales consist of instruments and consumables (which include reagents, flow cells, and microarrays) based on its proprietary technologies. Sequencing The company’s portfolio of sequencing platforms represents a family of systems that set the standard for productivity and accuracy among NGS technologies. Customers use the company’s platforms to perform whole-genome, de novo, and exome sequencing, and targeted resequencing of specific gene regions and genes. The company’s deoxyribonucleic acid (DNA) sequencing technology is based on its proprietary reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry. SBS tracks the addition of labeled nucleotides as the DNA chain is copied in a massively parallel fashion. The company’s SBS sequencing technology provides researchers with a range of applications and the ability to sequence even large mammalian genomes in a day rather than weeks or years. The company’s sequencing platforms could generate between 500 megabases and 1.8 terabases (equivalent to 16 human genomes) of genomic data in a single run, depending on the instrument and application. There are different price points per gigabase for each instrument, and for different applications, which range from small-genome, amplicon, and targeted gene-panel sequencing to population-scale whole human genome sequencing. Arrays Arrays are used for a range of DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variation analysis, gene expression analysis, and methylation analysis; and allow for the detection of various known genetic markers on a single array. The company’s BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that could perform many assays simultaneously. This facilitates large-scale analysis of genetic variation and biological function in a flexible manner. Using the company’s BeadArray technology, the company achieves high-throughput analysis through a high density of test sites per array and the ability to format arrays in various configurations. Both the company’s iScan array scanner system and its NextSeq 550 system could be used to image the arrays. Consumables The company has developed various library preparation and sequencing kits to simplify workflows and accelerate analysis. The company’s sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which could sequence exomes, specific genes, or other genomic regions of interest. The company’s sequencing kits improve the ability of its customers to characterize the target genome accurately. Customers use the company’s array-based genotyping consumables for a range of analyses, including various species, disease-related mutations, and genetic characteristics associated with cancer. Customers could select from a range of human, animal, and agriculturally relevant genome panels or create their own custom arrays to investigate various genetic markers targeting any species. Services In addition to selling products, the company provides whole-genome sequencing, genotyping, and noninvasive prenatal testing services. Human whole-genome sequencing services are provided through the company’s Clinical Laboratory Improvements A
(ILMN:Consolidated Issue Listed on NASDAQ Global Select )
5200 Illumina Way
San Diego, CA 92122
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for ILMN.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.